27 patents
Page 2 of 2
Utility
Methods for Telomere Length and Genomic Dna Quality Control Analysis In Pluripotent Stem Cells
8 Apr 21
The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells.
Michael G. WEST, Karen B. CHAPMAN, Walter D. FUNK
Filed: 22 Jul 20
Utility
Methods of screening embryonic progenitor cell lines
16 Feb 21
Aspects of the present invention include methods and compositions related to the production and use of numerous clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells with diverse molecular markers and having been cultured for >21 doublings of clonal expansion.
Michael West, Hal Sternberg, Karen Chapman
Filed: 18 Dec 17
Utility
Retinal Pigment Epithelium Cell Compositions
6 Jan 21
Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries.
Nir NETZER, Ofer WISER, Bat SHAHAF, Orit GAMBURG, Lior ROSENBERG BELMAKER, Dana HAYOUN NEEMAN, Osnat BOHANA KASHTAN
Filed: 27 Dec 18
Utility
Methods and formulations for orthopedic cell therapy
14 Dec 20
Aspects of the present invention include methods and compositions related to the production and use of clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells, in particular, said methods and compositions relate to methods of differentiating cells in the presence of members of the BMP family of growth factors and the applications of said cell lines in the treatment of degenerative orthopedic diseases such as osteoarthritis.
Michael West, Hal Sternberg
Filed: 11 Jul 12
Utility
Methods for telomere length and genomic DNA quality control analysis in pluripotent stem cells
17 Aug 20
The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells.
Michael D. West, Karen B. Chapman, Walter D. Funk
Filed: 22 May 16
Utility
Methods for Measuring Therapeutic Effects of Retinal Disease Therapies
18 Mar 20
Described herein are compositions and methods for treating retinal diseases or disorders using RPE cells.
Oscar Cuzzani, Francois Binette, Gary Hogge
Filed: 15 Mar 18
Utility
Methods for Differentiating Pluripotent Stem Cells In Dynamic Suspension Culture
18 Mar 20
Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGFβ/Activin/Nodal signaling and BMP signaling are provided.
Rekha R. Nair, Stephanie Kayser, Abhirath S. Parikh, Uzma Shoukat-Mumtaz, Erik Michael Whiteley, Nathan C. Manley, Craig R. Halberstadt
Filed: 18 Sep 19